3-V Biosciences 3vbio.com


Public list: BIO 2016 (619) Smart Money VCs (6328) Pharma Startups (4732) Cancer Therapeutics (1137)

3-V Biosciences is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V's antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy agains...Show all

3-V Biosciences is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that has been shown to block tumor cell sig...Show all

Company (Alive / Active)

Phone: 650-320-1760

Fax:

1050 Hamilton Court

Menlo Park, 94025
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
3-V Biosciences $111.8M Jul 5, 2016
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related 3-V Biosciences Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
New Enterprise AssociatesVenture CapitalMenlo Park, California, United StatesSeries D - II, Series D, Series C - II, Series C, Series B
Kleiner Perkins Caufield & ByersVenture CapitalMenlo Park, California, United StatesSeries D - II, Series D, Series C - II, Series C, Series B, Series A
Heller EhrmanSeries A
Qualifying Therapeutic Discovery ProjectGovernmentWashington, DC, United StatesGrant
Ally Bridge GroupVenture CapitalCentral, Hong KongSeries D
See all 8 investors

Competitors

Company Status Description Investors
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Heterocyclic modulators of lipid synthesis Oct 05, 2015 Nov 07, 2017 Patent
Heterocyclic modulators of lipid synthesis Mar 19, 2015 Apr 18, 2017 Patent
Heterocyclic modulators of lipid synthesis Dec 31, 2014 Aug 30, 2016 Patent
Heterocyclic modulators of lipid synthesis Mar 08, 2012 Oct 28, 2014 Patent
Heterocyclic modulators of lipid synthesis Nov 11, 2016 Application
See all 12 patents